Glucagon-induced growth hormone (GH) secretion was studied in healthy subjects under basal conditions (n = 18), and when treated with TRH (n = 10), cyproheptadine (n = 8) and pimozide (n = 6). With glucagon alone, the mean serum GH level significantly increased at 150 minutes and at 180 minutes. TRH administered as a bolus injection completely suppressed the GH response to glucagon. Cyproheptadine pretreatment resulted in a substantial suppression of the GH response to glucagon. A significant difference between basal and post-cyproheptadine GH levels was observed at 150 minutes after glucagon. Pimozide pretreatment was followed by a reduction of GH response to glucagon, but the difference between control and pimozide-treated groups was not significant. In conclusion, it is proposed that glucagon-induced GH secretion is at least partly mediated via serotoninergic mechanisms while significant dopaminergic involvement does not seem probable. It is further suggested that TRH plays a substantial inhibitory role in glucagon-stimulated SH secretion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2007-1019298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging trends in managed care pharmacy: A mixed-method study.
J Manag Care Spec Pharm
January 2025
Academy of Managed Care Pharmacy Foundation, Alexandria, VA.
Background: Over the past 5 years, managed care pharmacy has been shaped by a global pandemic, advancements in generative artificial intelligence (AI), Medicare drug price negotiation policies, and significant therapeutic developments. Collective intelligence methods can be used to anticipate future developments in practice to help organizations plan and develop new strategies around those changes.
Objective: To identify emerging trends in managed care pharmacy.
Heme oxygenase, biliverdin reductase, and bilirubin pathways regulate oxidative stress and insulin resistance: a focus on diabetes and therapeutics.
Clin Sci (Lond)
January 2025
Drug & Disease Discovery D3 Research Center, Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.
Metabolic and insulin-resistant diseases, such as type 2 diabetes mellitus (T2DM), have become major health issues worldwide. The prevalence of insulin resistance in the general population ranges from 15.5% to 44.
View Article and Find Full Text PDFRetinoids and retinoid-binding proteins: Unexpected roles in metabolic disease.
Curr Top Dev Biol
January 2025
Department of Pharmacology and Cleveland Center for Membrane and Structural Biology, Case Western Reserve University, Cleveland, OH, United States.
Alterations in tissue expression levels of both retinol-binding protein 2 (RBP2) and retinol-binding protein 4 (RBP4) have been associated with metabolic disease, specifically with obesity, glucose intolerance and hepatic steatosis. Our laboratories have shown that this involves novel pathways not previously considered as possible linkages between impaired retinoid metabolism and metabolic disease development. We have established both biochemically and structurally that RBP2 binds with very high affinity to very long-chain unsaturated 2-monoacylglycerols like the canonical endocannabinoid 2-arachidonoyl glycerol (2-AG) and other endocannabinoid-like substances.
View Article and Find Full Text PDFConsiderations for Perioperative Management Guidance Regarding GLP-1 Receptor Agonists: Evaluation of Current Practices and Future Directions.
Mil Med
January 2025
Department of Anesthesiology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA.
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly prevalent and have the potential to delay gastric emptying. The American Society of Anesthesiologists (ASA) released guidance regarding the perioperative management of patients receiving GLP-1 RAs, but it is unclear the extent to which hospitals in the U.S.
View Article and Find Full Text PDFAllodynia (skin tenderness) associated with semaglutide: A case series.
Am J Health Syst Pharm
January 2025
Veterans Health Care System of the Ozarks, Fayetteville, AR, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!